Physician profile
Ben Cooke
NPI 1528512803
$7,320.87
in general payments reported to CMS, 2019-2025
26 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $630 · 2021: $1,057 · 2022: $1,257 · 2023: $1,935 · 2024: $1,212 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,149.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,410.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,330.62 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $952.66 | 2022-2025 | |
| Lilly USA, LLC | $820.05 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $750.24 | 2021-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.18 | 2019-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Viiv Healthcare Company | $289.52 | 2022-2025 | Apretude |
| Genzyme Corporation | $129.86 | 2024-2025 | |
| Pfizer INC. | $115.66 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $112.62 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $110.15 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $102.60 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.97 | 2020-2024 | Farxiga |
| Amgen INC. | $89.14 | 2023-2025 | Otezla, Repatha, Evenity |
| Xeris Pharmaceuticals, INC. | $82.65 | 2022-2023 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $78.32 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $68.86 | 2019 | |
| Nestle Healthcare Nutrition INC. | $56.27 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $53.18 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $51.30 | 2022 | |
| Baxter Healthcare | $48.48 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Biotronik Nro, INC. | $44.79 | 2025 | Prospera |
| Daiichi Sankyo INC. | $43.74 | 2021 | |
| Bioventus LLC | $33.45 | 2021 | |
| Dexcom, INC. | $22.42 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $17.07 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Cooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.